Home » Dosing and Administration


To determine the appropriate dose and units required for your patient, fill in patient weight, creatinine clearance, infusion length and the unit choice you will be using to administer Aggrastat®.

The Only GPI With Contemporary Dosing

Aggrastat® Injection Premixed is supplied as a sterile solution in water for injection, for intravenous use, in 15 mL, 100 mL, and 250 mL single-use formats.

Dosing and Administration

Aggrastat Pharmacy - Dosing Summary

The recommended dosage is 25 mcg/kg administered intravenously within 5 minutes and then 0.15 mcg/kg/min for up to 18 hours.

Dosing Formulas for Aggrastat®

All patients

(using 250 mcg/mL bolus vial)

= 25 mcg/kg x body weight (kg)


250 mcg/mL

All patients

(using 50 mcg/mL units)

= 25 mcg/kg x body weight (kg)


50 mcg/mL

Infusion (mL/h)
Patients with CrCl>60mL/min

(using 50 mcg/mL units)

= 0.15 mcg/kg/min x body weight (kg) x 60 min/h


50 mcg/mL

Infusion (mL/h)
Patients with CrCl≤60mL/min

(using 50 mcg/mL units)

= 0.075 mcg/kg/min x body weight (kg) x 60 min/h


50 mcg/mL

Dosing Calculator

Administration Option is invalid.
Patient Weight is invalid.
Creatinine Clearance is invalid.


1. Bolus (Using 250 mcg/mL Bolus Vial)

2. Infusion (Using 50 mcg/mL Units)

Recommended Dosing & Administration

Administer intravenously 25 mcg/kg within 5 minutes and then 0.15 mcg/kg/min for up to 18 hours. In patients with creatinine clearance (CrCl) ≤ 60 mL/min, give 25 mcg/kg bolus within 5 minutes followed by an infusion of 0.075 mcg/kg/min for up to 18 hours.


By using this resource, you agree to the following: This Dosing Calculator is being provided “AS IS” and is intended for use only by qualified healthcare providers. All calculations should be confirmed before use. Medicure makes no claims as to the accuracy of the information contained herein. The information being provided is not a substitute for clinical judgment. Neither Medicure, nor any other party involved in the preparation or publication of this site, shall be liable to you or others for any decisions made or actions taken by you or others in reliance on this information.

Download the dosing and administration guide for Aggrastat®

Watch how to use Aggrastat® bolus vial with 100 mL vial (50 mcg/mL)

Play Video about Aggrastat Pharmacy Educational Video

Instructions for Bags

  • To open the 100 mL or 250 mL premixed bag, tear off its foil overpouch.
    • The plastic may be somewhat opaque because of moisture absorption during sterilization; the opacity will diminish gradually.
  • Check for leaks by squeezing the inner bag firmly; if any leaks are found or sterility is suspect then the solution should be discarded.
  • Do not use unless the solution is clear and the seal is intact.

Instructions for 100 mL Vial

  • Ensure seal is intact.
  • Remove vial cap.
  • Place vial on a flat surface, insert a vented IV set and open the vent.
  • Hang bottle by plastic hanger and adjust flow for appropriate dosing.

Drug Compatibilities

  • Aggrastat® can be administered in the same intravenous line as heparin, atropine sulfate, dobutamine, dopamine, epinephrine hydrochloride (HCl), famotidine injection, furosemide, lidocaine, midazolam HCl, morphine sulfate, nitroglycerin, potassium chloride, and propranolol HCl.
  • Do not administer Aggrastat® through the same IV line as diazepam.
  • Do not add other drugs or remove solution directly from the bag with a syringe.

Calculate How Many Units You Need For Your Patient

Patient Weight is invalid.
Creatinine Clearance is invalid.
Infusion Length is invalid.
Unit Choice is invalid.

Dosing Results

Units Needed

Important Safety Information


Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).


  • Known hypersensitivity to any component of Aggrastat®.
  • History of thrombocytopenia with prior exposure to Aggrastat®.
  • Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.

Warnings and Precautions:

  • Aggrastat® can cause serious bleeding. Most bleeding associated with Aggrastat® occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Concomitant use of fibrinolytics, anticoagulants and antiplatelet drugs increases the risk of bleeding. If bleeding cannot be controlled, discontinue Aggrastat®.
  • Thrombocytopenia: discontinue Aggrastat® and heparin.

Adverse Reactions:

  • Bleeding is the most commonly reported adverse reaction.

For additional information, refer to the full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch
or call 1-800-FDA-1088.